Fluticasone Propionate And Salmeterol Hfa Aerosol, Metered
Product Images NDC 66993-086

19 FDA label images from Prasco Laboratories · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol Hfa (NDC 66993-086). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Prasco Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Chemical Structure (Fp Sal Hfa Spl Graphic 01)

Fluticasone Chemical Structure (Fp Sal Hfa Spl Graphic 01)
Chemical structure of fluticasone propionate, one of the active ingredients in Fluticasone Propionate and Salmeterol HFA aerosol inhalation.*
FDA Label Image

Salmeterol Chemical Structure (Fp Sal Hfa Spl Graphic 02)

Salmeterol Chemical Structure (Fp Sal Hfa Spl Graphic 02)
Chemical structure of the active ingredients fluticasone propionate and salmeterol xinafoate, shown as a structural formula diagram.*
FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects Previously Treated With Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Fp Sal Hfa Spl Graphic 03)

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects Previously Treated With Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Fp Sal Hfa Spl Graphic 03)
A line graph depicting the percentage change in FEV1 over 12 weeks and at endpoint for four groups: Fluticasone propionate and salmeterol HFA inhalation aerosol 45 mcg/21 mcg, Fluticasone propionate inhalation aerosol 44 mcg, Salmeterol inhalation aerosol 21 mcg, and placebo. The graph shows time on the x-axis (weeks) and percentage change in FEV1 on the y-axis, with each group represented by different markers.*
FDA Label Image

Figure 2. Mean Percent Change From Baseline In Morning Peak Expiratory Flow In Subjects Previously Treated With Inhaled Corticosteroids (trial 4) (Fp Sal Hfa Spl Graphic 04)

Figure 2. Mean Percent Change From Baseline In Morning Peak Expiratory Flow In Subjects Previously Treated With Inhaled Corticosteroids (trial 4) (Fp Sal Hfa Spl Graphic 04)
A line graph comparing the percent change in AM PEF (morning peak expiratory flow) over 12 weeks for three respiratory inhalation treatments: Fluticasone propionate and salmeterol HFA aerosol 230 mcg/21 mcg (two inhalations twice daily), ADVAIR DISKUS 500 mcg/50 mcg (one inhalation twice daily), and Fluticasone propionate inhalation aerosol 220 mcg (two inhalations twice daily). The x-axis shows the study weeks, and the y-axis shows percent change in AM PEF. Data points include subject numbers at select weeks.*
FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Fp Sal Hfa Spl Graphic 05)

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Fp Sal Hfa Spl Graphic 05)
A line graph showing the percentage change in FEV1 over 12 hours following inhalation treatments. The chart compares Fluticasone propionate and salmeterol HFA 45 mcg/21 mcg, Fluticasone propionate 44 mcg, Salmeterol 21 mcg, and placebo, with different symbols representing each group. The graph illustrates the changes from baseline at Day 1 and tracks effectiveness over time for each treatment group.*
FDA Label Image

Figure 4. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Fp Sal Hfa Spl Graphic 06)

Figure 4. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Fp Sal Hfa Spl Graphic 06)
A line graph displaying percent change in FEV1 relative to Day 1 baseline over 12 hours for four treatment groups: fluticasone propionate and salmeterol HFA inhalation aerosol 45 mcg/21 mcg twice daily, fluticasone propionate inhalation aerosol 44 mcg twice daily, salmeterol inhalation aerosol 21 mcg twice daily, and placebo. The x-axis represents time in hours, and the y-axis shows percent change in FEV1.*
FDA Label Image

Figure A (Fp Sal Hfa Spl Graphic 07)

Figure A (Fp Sal Hfa Spl Graphic 07)
Illustration showing parts of the Fluticasone Propionate and Salmeterol HFA metered aerosol inhaler including a metal canister, purple plastic actuator, purple mouthpiece, a counter display with the number 124, and a light purple cap.*
FDA Label Image

Figure B (Fp Sal Hfa Spl Graphic 08)

Figure B (Fp Sal Hfa Spl Graphic 08)
An instructional diagram showing two hands holding an inhaler and a separate small cap, with an arrow indicating the cap being placed onto or removed from the inhaler mouthpiece, related to proper handling or use of an aerosol inhaler device.*
FDA Label Image

Figure C (Fp Sal Hfa Spl Graphic 09)

Figure C (Fp Sal Hfa Spl Graphic 09)
Illustration showing a person using a metered-dose inhaler spray. The image depicts a hand pressing down on the inhaler to release a spray, with the user's mouth near the mouthpiece. A cap is shown removed and placed nearby. The inhaler body displays a dose counter reading '125.'*
FDA Label Image

Figure D (Fp Sal Hfa Spl Graphic 10)

Figure D (Fp Sal Hfa Spl Graphic 10)
An instructional line drawing showing a hand holding an aerosol inhaler with a dose counter indicating 120 doses remaining. The inhaler is a metered aerosol device, likely used for respiratory inhalation therapy.*
FDA Label Image

Figure E (Fp Sal Hfa Spl Graphic 11)

Figure E (Fp Sal Hfa Spl Graphic 11)
An instructional illustration showing correct use of an inhaler with mouthpiece-down position. The diagram labels the inhaler parts, including a purple mouthpiece and a light purple cap, with a hand holding the device ready for use.*
FDA Label Image

Figure F (Fp Sal Hfa Spl Graphic 12)

Figure F (Fp Sal Hfa Spl Graphic 12)
Instructional illustration showing a person exhaling with the text 'Breathe out as much air as you can,' accompanied by an arrow indicating airflow outward from the mouth. This likely relates to inhalation technique guidance for respiratory drug use.*
FDA Label Image

Figure G (Fp Sal Hfa Spl Graphic 13)

Figure G (Fp Sal Hfa Spl Graphic 13)
An instructional illustration showing a person holding a metered dose inhaler near their mouth, with an arrow indicating to push down on the inhaler and breathe in the medication.*
FDA Label Image

Figure H (Fp Sal Hfa Spl Graphic 14)

Figure H (Fp Sal Hfa Spl Graphic 14)
An instructional illustration showing a person rinsing their mouth by spitting water into a sink, with a glass of water and a faucet visible. This is commonly used to depict post-inhalation mouth rinsing to reduce side effects associated with inhaled medications.*
FDA Label Image

Figure I (Fp Sal Hfa Spl Graphic 15)

Figure I (Fp Sal Hfa Spl Graphic 15)
An instructional illustration showing correct and incorrect aerosol spray from a metered inhaler. The top image labeled 'Not blocked' shows a clear spray mist, while the bottom image labeled 'Blocked' shows a partially obstructed spray. The illustration emphasizes proper inhaler technique for effective medication delivery.*
FDA Label Image

Figure J (Fp Sal Hfa Spl Graphic 16)

Figure J (Fp Sal Hfa Spl Graphic 16)
Instructional diagram showing a hand holding an inhaler and using a swab or similar tool to clean or manipulate the actuator or mouthpiece area of the metered-dose inhaler. The image emphasizes rotating or circular motion for maintenance or preparation.*
FDA Label Image

Fluticasone Propionate And Salmeterol Hfa 45 Mcg-21 Mcg 120 Dose Carton (Fp Sal Hfa Spl Graphic 17)

Fluticasone Propionate And Salmeterol Hfa 45 Mcg-21 Mcg 120 Dose Carton (Fp Sal Hfa Spl Graphic 17)
Label for Fluticasone Propionate and Salmeterol HFA Inhalation Aerosol by Prasco Laboratories, strength 45 mcg/21 mcg. The label includes usage instructions, dosage details, and states 120 metered actuations with a net weight of 12 g. It specifies the inhalation route and that the product is prescription only.*
FDA Label Image

Fluticasone Propionate And Salmeterol Hfa 115 Mcg-21 Mcg 120 Dose Carton (Fp Sal Hfa Spl Graphic 18)

Fluticasone Propionate And Salmeterol Hfa 115 Mcg-21 Mcg 120 Dose Carton (Fp Sal Hfa Spl Graphic 18)
Label for Fluticasone Propionate and Salmeterol HFA Inhalation Aerosol, 115 mcg/21 mcg strength. The label indicates it is for oral inhalation using the specified actuator and includes 120 metered actuations per container. The product is manufactured by Prasco Laboratories and the net weight is 12 grams. Additional information on active ingredients and prescription status is also provided.*
FDA Label Image

Fluticasone Propionate And Salmeterol Hfa 230 Mcg-21 Mcg 120 Dose Carton (Fp Sal Hfa Spl Graphic 19)

Fluticasone Propionate And Salmeterol Hfa 230 Mcg-21 Mcg 120 Dose Carton (Fp Sal Hfa Spl Graphic 19)
Label for Fluticasone Propionate and Salmeterol HFA Inhalation Aerosol 230 mcg/21 mcg by Prasco Laboratories. The label states it is for oral inhalation with the specified actuator only, containing 120 metered actuations with a net weight of 12 g. The label includes NDC 66993-088-96 and a small image of the purple inhaler canister.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.